<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726037</url>
  </required_header>
  <id_info>
    <org_study_id>200732</org_study_id>
    <nct_id>NCT00726037</nct_id>
  </id_info>
  <brief_title>A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Riveria Country Club Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the duration of T reg suppression in patients with
      metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for
      future dendritic cell vaccine administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improved insight into the epidemiology and biology, pancreatic cancer remains a
      significant health problem as evidenced by the disappointing survival rates associated with
      advanced disease. Because of its aggressive growth and early metastatic dissemination, only
      20% of patients can be treated by surgery at the time of diagnosis. Furthermore, the overall
      5-year survival rate of stage IV disease is &lt; 5% [1-3] despite chemotherapy. With such a
      dismal outlook, it is obvious that novel treatment strategies are required.

      There is limited experience in the literature with the use of Ontak in the treatment of
      metastatic pancreatic cancer. Viehl, et al, demonstrated in a murine model of pancreatic
      cancer, that ontak combined with whole tumor vaccine led to a significantly increased T
      cell-dependent antitumor immune response, as well as an improved survival compared to
      controls. Our group has an active trial at Loyola evaluating the role of dendritic cell
      vaccine in patients with unresectable, not metastatic, pancreatic cancer. Preliminary data
      suggests a correlation with time to progression and restoration of Tregs following an initial
      decrease after the DC injection. The goal of the current proposal is to determine the time
      point at which the Tregs reach the nadir within four weeks of ontak injection. When this is
      determined, we will eventually propose administering ontak followed by DC vaccine at the
      nadir Treg time point for patients with unresectable pancreatic cancer
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Collaborator withdrew support due to a drug supply interruption.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer</measure>
    <time_frame>days 8, 12 ,19,26 and 33 post administration</time_frame>
    <description>The duration of T reg suppression from a fractionated dose of Ontak in patients will be measured in patients with metastatic pancreatic cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal Time for Future Dendritic Cell Vaccine Administration</measure>
    <time_frame>33 Days</time_frame>
    <description>The goal is to define the optimal time with 95% sensitivity and 95% specificity for future dendritic cell vaccine administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ontak</intervention_name>
    <description>One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Denileukin diftitox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients and nonpregnant, nonlactating female patient &gt; 18 years old

          -  Histologic diagnosis of pancreatic cancer with distant disease seen on CT or MRI with
             no prior chemotherapy or radiotherapy for a least 4 weeks

          -  Karnofsky performance status equal to or greater than 70%

          -  Life expectancy of at least 3 months.

          -  No uncontrolled pain

          -  No symptoms of bowel obstruction

          -  Women with child bearing potential must agree to use adequate contraceptives. If she
             should become pregnant she needs to inform the treating physician

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Positive serologic testing for HIV, AIDS, human T-cell lymphotrophic virus type 1,
             hepatitis B, or hepatitis C.

          -  Hemoglobin &lt;9g/dL; hematocrit &lt;27%; platelets &lt;100,000/ U/L without transfusion
             support

          -  Creatinine &gt; 1.8 mg/dL

          -  Serum albumin &lt; 2.0 mg/dL

          -  AST &gt; 3X ULN; ALT &gt; 3X ULN

          -  Bilirubin &gt; 1.8

          -  Uncontrolled angina, arrhythmias, bronchospasm, hypertension, or hypercalcemia.

          -  Corticosteroid use within 28 days

          -  Chemotherapy or radiation within 28 days

          -  Bacteremia or other signs of active systemic infection

          -  History of autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margo Shoup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996 Mar;223(3):273-9.</citation>
    <PMID>8604907</PMID>
  </reference>
  <reference>
    <citation>Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996 May;83(5):625-31.</citation>
    <PMID>8689203</PMID>
  </reference>
  <reference>
    <citation>Warshaw AL, Fern√°ndez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992 Feb 13;326(7):455-65. Review.</citation>
    <PMID>1732772</PMID>
  </reference>
  <reference>
    <citation>Zwar TD, van Driel IR, Gleeson PA. Guarding the immune system: suppression of autoimmunity by CD4+CD25+ immunoregulatory T cells. Immunol Cell Biol. 2006 Dec;84(6):487-501. Epub 2006 Sep 5. Review.</citation>
    <PMID>16956386</PMID>
  </reference>
  <reference>
    <citation>Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007 Mar;56(3):271-85. Epub 2006 Jul 4. Review.</citation>
    <PMID>16819631</PMID>
  </reference>
  <reference>
    <citation>Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.</citation>
    <PMID>15322536</PMID>
  </reference>
  <reference>
    <citation>Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002 May 1;168(9):4272-6.</citation>
    <PMID>11970966</PMID>
  </reference>
  <reference>
    <citation>Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007 Nov;56(11):1743-53. Epub 2007 May 9.</citation>
    <PMID>17487490</PMID>
  </reference>
  <reference>
    <citation>Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cancer. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):764-70. Epub 2007 Feb 16. Review.</citation>
    <PMID>17309663</PMID>
  </reference>
  <reference>
    <citation>Linehan DC, Goedegebuure PS. CD25+ CD4+ regulatory T-cells in cancer. Immunol Res. 2005;32(1-3):155-68. Review.</citation>
    <PMID>16106066</PMID>
  </reference>
  <reference>
    <citation>Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006 Sep;13(9):1252-8. Epub 2006 Sep 3.</citation>
    <PMID>16952047</PMID>
  </reference>
  <reference>
    <citation>Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, Maekawa Y, Yasutomo K, Shimada M. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 2006 Nov;33(4):386-90.</citation>
    <PMID>17079944</PMID>
  </reference>
  <reference>
    <citation>Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006 Sep 15;12(18):5423-34.</citation>
    <PMID>17000676</PMID>
  </reference>
  <reference>
    <citation>Figgitt DP, Lamb HM, Goa KL. Denileukin diftitox. Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. Review.</citation>
    <PMID>11702307</PMID>
  </reference>
  <reference>
    <citation>Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005 Dec;115(12):3623-33. Epub 2005 Nov 23.</citation>
    <PMID>16308572</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <results_first_submitted>April 26, 2013</results_first_submitted>
  <results_first_submitted_qc>July 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2016</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Denileukin diftitox</keyword>
  <keyword>Metastatic Pancreatic Cancer</keyword>
  <keyword>Ontak</keyword>
  <keyword>Regulatory T-cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study began on 06/18/2008 and ended on 01/09/2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ontak</title>
          <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ontak</title>
          <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer</title>
        <description>The duration of T reg suppression from a fractionated dose of Ontak in patients will be measured in patients with metastatic pancreatic cancer.</description>
        <time_frame>days 8, 12 ,19,26 and 33 post administration</time_frame>
        <population>Zero participants were analyzed, because the manufacturer withdrew support for the study due to a drug supply interruption</population>
        <group_list>
          <group group_id="O1">
            <title>Ontak</title>
            <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer</title>
          <description>The duration of T reg suppression from a fractionated dose of Ontak in patients will be measured in patients with metastatic pancreatic cancer.</description>
          <population>Zero participants were analyzed, because the manufacturer withdrew support for the study due to a drug supply interruption</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optimal Time for Future Dendritic Cell Vaccine Administration</title>
        <description>The goal is to define the optimal time with 95% sensitivity and 95% specificity for future dendritic cell vaccine administration</description>
        <time_frame>33 Days</time_frame>
        <population>Zero participants were analyzed, because the manufacturer withdrew support for the study due to a drug supply interruption</population>
        <group_list>
          <group group_id="O1">
            <title>Ontak</title>
            <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Time for Future Dendritic Cell Vaccine Administration</title>
          <description>The goal is to define the optimal time with 95% sensitivity and 95% specificity for future dendritic cell vaccine administration</description>
          <population>Zero participants were analyzed, because the manufacturer withdrew support for the study due to a drug supply interruption</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each participant, adverse events were assessed from baseline through end of study (i.e., 33 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ontak</title>
          <description>Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was prematurely terminated, because the study drug Ontak is no longer supplied by the manufacturer for this study. Data is not analyzed for any outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margret Shoup</name_or_title>
      <organization>Northwestern Medicine Regional Medical Group</organization>
      <phone>630-352-5450</phone>
      <email>MSHOUP@lumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

